Lakefront Biotherapeutics NV — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications3liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
GLPG1690The main purpose of the study is to see if GLPG1690 helps (together with the standard of care treatment) in the treatment of the skin and other areas affected by systemic sclerosis. Another aim is to find out how safe/well tolerated GLPG1690 will be and whether there are any side effects. The study will also look at other things, including whether the study drug affects disease progression and also if it changes any aspect of the quality of life.	SEP	Phase 2	Ralentissement de la progression	United States, Belgium, Germany, Italy, Spain, United Kingdom	À vérifier
GLPG1690The main purpose of the study is to see if GLPG1690 helps (together with the standard of care treatment) in the treatment of the skin and other areas affected by systemic sclerosis. Another aim is to find out how safe/well tolerated GLPG1690 will be and whether there are any side effects. The study will also look at other things, including whether the study drug affects disease progression and also if it changes any aspect of the quality of life.	SEP	Phase 2	Ralentissement de la progression	United States, Belgium, Germany, Italy, Spain, United Kingdom	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
GLPG1690	SEP	Phase 2	NCT03798366	A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis	COMPLETED

Publications

3

Molécule	Indication / population	Titre	Journal	Date
GLPG1690		Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials.	JAMA
GLPG1690		Rational design and identification of potent imidazole-fused Autotaxin inhibitors for treatment of idiopathic pulmonary fibrosis.	European journal of medicinal chemistry
GLPG1690		Autotaxin inhibitors: an updated patent review (2021-present).	Expert opinion on therapeutic patents